发布求助
文献互助 智能选刊 最新文献

Cancer Cell最新文献

筛选
英文 中文
Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics 单细胞空间多组学揭示癌症相关成纤维细胞的保守空间亚型和细胞邻域
IF 50.3 1区 医学
Cancer Cell Pub Date : 2025-03-27 DOI: 10.1016/j.ccell.2025.03.004
Yunhe Liu, Ansam Sinjab, Jimin Min, Guangchun Han, Francesca Paradiso, Yuanyuan Zhang, Ruiping Wang, Guangsheng Pei, Yibo Dai, Yang Liu, Kyung Serk Cho, Enyu Dai, Akshay Basi, Jared K. Burks, Kimal I. Rajapakshe, Yanshuo Chu, Jiahui Jiang, Daiwei Zhang, Xinmiao Yan, Paola A. Guerrero, Linghua Wang
{"title":"Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics","authors":"Yunhe Liu, Ansam Sinjab, Jimin Min, Guangchun Han, Francesca Paradiso, Yuanyuan Zhang, Ruiping Wang, Guangsheng Pei, Yibo Dai, Yang Liu, Kyung Serk Cho, Enyu Dai, Akshay Basi, Jared K. Burks, Kimal I. Rajapakshe, Yanshuo Chu, Jiahui Jiang, Daiwei Zhang, Xinmiao Yan, Paola A. Guerrero, Linghua Wang","doi":"10.1016/j.ccell.2025.03.004","DOIUrl":"https://doi.org/10.1016/j.ccell.2025.03.004","url":null,"abstract":"Cancer-associated fibroblasts (CAFs) are a multifaceted cell population essential for shaping the tumor microenvironment (TME) and influencing therapy responses. Characterizing the spatial organization and interactions of CAFs within complex tissue environments provides critical insights into tumor biology and immunobiology. In this study, through integrative analyses of over 14 million cells from 10 cancer types across 7 spatial transcriptomics and proteomics platforms, we discover, validate, and characterize four distinct spatial CAF subtypes. These subtypes are conserved across cancer types and independent of spatial omics platforms. Notably, they exhibit distinct spatial organizational patterns, neighboring cell compositions, interaction networks, and transcriptomic profiles. Their abundance and composition vary across tissues, shaping TME characteristics, such as levels, distribution, and state composition of tumor-infiltrating immune cells, tumor immune phenotypes, and patient survival. This study enriches our understanding of CAF spatial heterogeneity in cancer and paves the way for novel approaches to target and modulate CAFs.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"1 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143713597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leveraging real-world data to advance biomarker discovery and precision oncology 利用真实世界的数据来推进生物标志物的发现和精确肿瘤学
IF 50.3 1区 医学
Cancer Cell Pub Date : 2025-03-27 DOI: 10.1016/j.ccell.2025.03.012
Jiaqian Luo, David B. Solit
{"title":"Leveraging real-world data to advance biomarker discovery and precision oncology","authors":"Jiaqian Luo, David B. Solit","doi":"10.1016/j.ccell.2025.03.012","DOIUrl":"https://doi.org/10.1016/j.ccell.2025.03.012","url":null,"abstract":"Precision oncology is predicated on the availability of robust biomarkers deployed at scale at the point of care. Although simple in conception, precision oncology often fails in practice because of the limitations of current diagnostic platforms, the emergence of drug resistance, and an incomplete understanding of cancer pathogenesis and the host immune response. Here, we discuss using real-world data, including exceptional responder analyses, to identify biomarkers of therapy response and strategies for overcoming barriers to the broader adoption of precision oncology paradigms.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"57 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143713600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy 为免疫检查点抑制剂治疗导航已建立的和新兴的生物标志物
IF 50.3 1区 医学
Cancer Cell Pub Date : 2025-03-27 DOI: 10.1016/j.ccell.2025.03.006
Stephen L. Wang, Timothy A. Chan
{"title":"Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy","authors":"Stephen L. Wang, Timothy A. Chan","doi":"10.1016/j.ccell.2025.03.006","DOIUrl":"https://doi.org/10.1016/j.ccell.2025.03.006","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have improved outcomes of patients with many different cancers. These antibodies target molecules such as programmed cell death 1 (PD-1) or cytotoxic T lymphocyte associated protein 4 (CTLA-4) which normally function to limit immune activity. Treatment with ICIs reactivates T cells to destroy tumor cells in a highly specific manner, which in some patients, results in dramatic remissions and durable disease control. Over the last decade, much effort has been directed at characterizing factors that drive efficacy and resistance to ICI therapy. Food and Drug Administration (FDA)-approved biomarkers for ICI therapy have facilitated more judicious treatment of cancer patients and transformed the field of precision oncology. Yet, adaptive immunity against cancers is complex, and newer data have revealed the potential utility of other biomarkers. In this review, we discuss the utility of currently approved biomarkers and highlight how emerging biomarkers can further improve the identification of patients who benefit from ICIs.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"61 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143713644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit 新辅助免疫检查点治疗：使洞察基本的人类免疫学和临床效益
IF 50.3 1区 医学
Cancer Cell Pub Date : 2025-03-20 DOI: 10.1016/j.ccell.2025.03.005
Kristen E. Pauken, Omar Alhalabi, Sangeeta Goswami, Padmanee Sharma
{"title":"Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit","authors":"Kristen E. Pauken, Omar Alhalabi, Sangeeta Goswami, Padmanee Sharma","doi":"10.1016/j.ccell.2025.03.005","DOIUrl":"https://doi.org/10.1016/j.ccell.2025.03.005","url":null,"abstract":"While immune checkpoint therapy (ICT) has revolutionized cancer treatment, most patients with advanced disease fail to achieve durable benefit. To address this challenge, it is essential to integrate mechanistic research with clinical studies to: (1) understand response mechanisms, (2) identify patient-specific resistance pathways, (3) develop biomarkers for patient selection, and (4) design novel therapies to overcome resistance. We propose that incorporating “direct-in-patient” studies into clinical trials is crucial for bridging the gap between fundamental science and clinical oncology. In this review, we first highlight recent clinical success of ICT in the neoadjuvant setting, where treatment is given in earlier disease stages to improve outcomes. We then explore how neoadjuvant clinical trials could be utilized to drive mechanistic laboratory-based investigations. Finally, we discuss novel scientific concepts that will potentially aid in overcoming resistance to ICT, which will require future clinical trials to understand their impact on human immune responses.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"91 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143660411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Of HIFs and hERVs: Neoantigen generation in kidney cancer hif和herv：肾癌中新抗原的产生
IF 50.3 1区 医学
Cancer Cell Pub Date : 2025-03-20 DOI: 10.1016/j.ccell.2025.03.001
Nicholas J. Salgia, Nazli Dizman, Sumanta K. Pal
{"title":"Of HIFs and hERVs: Neoantigen generation in kidney cancer","authors":"Nicholas J. Salgia, Nazli Dizman, Sumanta K. Pal","doi":"10.1016/j.ccell.2025.03.001","DOIUrl":"https://doi.org/10.1016/j.ccell.2025.03.001","url":null,"abstract":"New evidence published in <em>Cell</em> provides insight into the interplay between hypoxia-inducible factor activity and downstream neoantigen production in clear cell renal cell carcinoma (ccRCC). Jiang et al. show that HIF2α regulates expression of immunogenic human endogenous retroelements, with implications for antitumor immunity and immunotherapy responsiveness in ccRCC.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"55 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143660410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Horizontal mitochondrial transfer in cancer biology: Potential clinical relevance 水平线粒体转移在癌症生物学：潜在的临床意义
IF 50.3 1区 医学
Cancer Cell Pub Date : 2025-03-20 DOI: 10.1016/j.ccell.2025.03.002
Michael V. Berridge, Renata Zobalova, Stepana Boukalova, Andrés Caicedo, Stuart A. Rushworth, Jiri Neuzil
{"title":"Horizontal mitochondrial transfer in cancer biology: Potential clinical relevance","authors":"Michael V. Berridge, Renata Zobalova, Stepana Boukalova, Andrés Caicedo, Stuart A. Rushworth, Jiri Neuzil","doi":"10.1016/j.ccell.2025.03.002","DOIUrl":"https://doi.org/10.1016/j.ccell.2025.03.002","url":null,"abstract":"Recent research highlights horizontal mitochondrial transfer as a key biological phenomenon linked to cancer onset and progression. The transfer of mitochondria and their genomes between cancer and non-cancer cells shifts our understanding of intercellular gene trafficking, increasing the metabolic fitness of cancer cells and modulating antitumor immune responses. This process not only facilitates tumor progression but also presents potential therapeutic opportunities.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"26 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143660407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Small-molecule RNA therapeutics to target prostate cancer 靶向前列腺癌的小分子RNA疗法
IF 50.3 1区 医学
Cancer Cell Pub Date : 2025-03-20 DOI: 10.1016/j.ccell.2025.02.027
Duygu Kuzuoglu-Ozturk, Hao G. Nguyen, Lingru Xue, Emma Figueredo, Vishvak Subramanyam, Isabelle Liu, Kenya Bonitto, Ashish Noronha, Adrianna Dabrowska, Janet E. Cowan, Juan A. Oses-Prieto, Alma L. Burlingame, Stephen T. Worland, Peter R. Carroll, Davide Ruggero
{"title":"Small-molecule RNA therapeutics to target prostate cancer","authors":"Duygu Kuzuoglu-Ozturk, Hao G. Nguyen, Lingru Xue, Emma Figueredo, Vishvak Subramanyam, Isabelle Liu, Kenya Bonitto, Ashish Noronha, Adrianna Dabrowska, Janet E. Cowan, Juan A. Oses-Prieto, Alma L. Burlingame, Stephen T. Worland, Peter R. Carroll, Davide Ruggero","doi":"10.1016/j.ccell.2025.02.027","DOIUrl":"https://doi.org/10.1016/j.ccell.2025.02.027","url":null,"abstract":"Tuning protein expression by targeting RNA structure using small molecules is an unexplored avenue for cancer treatment. To understand whether this vulnerability could be therapeutically targeted in the most lethal form of prostate cancer, castration-resistant prostate cancer (CRPC), we use a clinical small molecule, zotatifin, that targets the RNA helicase and translation factor eukaryotic initiation factor 4A (eIF4A). Zotatifin represses tumorigenesis in patient-derived and xenograft models and prolonged survival <em>in vivo</em> alongside hormone therapy. Genome-wide transcriptome, translatome, and proteomic analysis reveals two important translational targets: androgen receptor (AR), a key oncogene in CRPC, and hypoxia-inducible factor 1A (HIF1A), an essential cancer modulator in hypoxia. We solve the structure of the 5′ UTRs of these oncogenic mRNAs and strikingly observe complex structural remodeling of these select mRNAs by this small molecule. Remarkably, tumors treated with zotatifin become more sensitive to anti-androgen therapy and radiotherapy. Therefore, “translatome therapy” provides additional strategies to treat the deadliest cancers.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"36 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143660415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effective targeting of PDGFRA-altered high-grade glioma with avapritinib 阿伐替尼有效靶向pdgfr改变的高级别胶质瘤
IF 50.3 1区 医学
Cancer Cell Pub Date : 2025-03-13 DOI: 10.1016/j.ccell.2025.02.018
Lisa Mayr, Sina Neyazi, Kallen Schwark, Maria Trissal, Alexander Beck, Jenna Labelle, Sebastian K. Eder, Liesa Weiler-Wichtl, Joana G. Marques, Carlos A.O. de Biagi-Junior, Costanza Lo Cascio, Owen Chapman, Sunita Sridhar, Rishaan Kenkre, Aditi Dutta, Shanqing Wang, Jessica Wang, Olivia Hack, Andrezza Nascimento, Cuong M. Nguyen, Mariella G. Filbin
{"title":"Effective targeting of PDGFRA-altered high-grade glioma with avapritinib","authors":"Lisa Mayr, Sina Neyazi, Kallen Schwark, Maria Trissal, Alexander Beck, Jenna Labelle, Sebastian K. Eder, Liesa Weiler-Wichtl, Joana G. Marques, Carlos A.O. de Biagi-Junior, Costanza Lo Cascio, Owen Chapman, Sunita Sridhar, Rishaan Kenkre, Aditi Dutta, Shanqing Wang, Jessica Wang, Olivia Hack, Andrezza Nascimento, Cuong M. Nguyen, Mariella G. Filbin","doi":"10.1016/j.ccell.2025.02.018","DOIUrl":"https://doi.org/10.1016/j.ccell.2025.02.018","url":null,"abstract":"PDGFRA is crucial to tumorigenesis and frequently genomically altered in high-grade glioma (HGG). In a comprehensive dataset of pediatric HGG (<em>n</em> = 261), we detect <em>PDGFRA</em> mutations and/or amplifications in 15% of cases, suggesting PDGFRA as a therapeutic target. We reveal that the PDGFRA/KIT inhibitor avapritinib shows (1) selectivity for PDGFRA inhibition, (2) distinct patterns of subcellular effects, (3) <em>in vitro</em> and <em>in vivo</em> activity in patient-derived HGG models, and (4) effective blood-brain barrier penetration in mice and humans. Furthermore, we report preliminary clinical real-world experience using avapritinib in pediatric and young adult patients with predominantly recurrent/refractory <em>PDGFRA</em>-altered HGG (<em>n</em> = 8). Our early data demonstrate that avapritinib is well tolerated and results in radiographic response in 3/7 cases, suggesting a potential role for avapritinib in the treatment of HGG with specific <em>PDGFRA</em> alterations<strong>.</strong> Overall, these translational results underscore the therapeutic potential of PDGFRA inhibition with avapritinib in HGG.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"39 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143608519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PAI-1-driven SFRP2high cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy pai -1驱动的sfrp2高癌相关成纤维细胞劫持放射免疫治疗的体外效应
IF 50.3 1区 医学
Cancer Cell Pub Date : 2025-03-13 DOI: 10.1016/j.ccell.2025.02.024
Yan-Pei Zhang, Ze-Qin Guo, Xiao-Ting Cai, Zi-Xuan Rong, Yuan Fang, Jia-Qi Chen, Kui-Mao Zhuang, Min-Jie Ruan, Si-Cong Ma, Le-Yi Lin, Duan-Duan Han, Yang-Si Li, Yuan-Yuan Wang, Jian Wang, Chuan-Hui Cao, Xin-Ran Tang, Qian-Kun Xie, Yue Chen, Yan Lin, Jia-Le Tan, Zhong-Yi Dong
{"title":"PAI-1-driven SFRP2high cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy","authors":"Yan-Pei Zhang, Ze-Qin Guo, Xiao-Ting Cai, Zi-Xuan Rong, Yuan Fang, Jia-Qi Chen, Kui-Mao Zhuang, Min-Jie Ruan, Si-Cong Ma, Le-Yi Lin, Duan-Duan Han, Yang-Si Li, Yuan-Yuan Wang, Jian Wang, Chuan-Hui Cao, Xin-Ran Tang, Qian-Kun Xie, Yue Chen, Yan Lin, Jia-Le Tan, Zhong-Yi Dong","doi":"10.1016/j.ccell.2025.02.024","DOIUrl":"https://doi.org/10.1016/j.ccell.2025.02.024","url":null,"abstract":"The abscopal effect of radioimmunotherapy, wherein tumor shrinkage occurs beyond the irradiated field, is therapeutically promising but clinically rare. The mechanisms underlying this effect remain elusive. Here, <em>in vivo</em> genome-wide CRISPR screening identifies SFRP2 as a potential stromal regulator of the abscopal effect. SFRP2 exhibits cancer-associated fibroblast (CAF)-specific expression and radioimmunotherapy-mediated upregulation in unirradiated tumors. Conditional <em>Sfrp2</em> knockout in CAFs boosts the abscopal effect by rewiring the vascular-immune microenvironment to promote CD8<sup>+</sup> T cell recruitment to unirradiated tumors. <em>In vivo</em> lineage tracing reveals that elevated SFRP2 correlates with radioimmunotherapy-driven pericyte lineage commitment. Serum proteomics reveals that irradiated-tumor-secreted PAI-1 triggers distant tumor pericyte cell-fate transition into SFRP2<sup>high</sup> CAFs via the LRP1/p65 axis. Pharmacologically blocking SFRP2 or PAI-1 enhances the abscopal effect in humanized patient-derived xenograft models. Our findings collectively illustrate that PAI-1-induced SFRP2<sup>high</sup> CAFs serve as critical stromal regulator to hijack the abscopal effect, providing promising targets for enhancing radioimmunotherapy effectiveness.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"183 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143608698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Turning the kaleidoscope: Innovations shaping the future of clinical trial design 转动万花筒：塑造临床试验设计未来的创新
IF 50.3 1区 医学
Cancer Cell Pub Date : 2025-03-13 DOI: 10.1016/j.ccell.2025.02.019
Grégoire Marret, Mercedes Herrera, Lillian L. Siu
{"title":"Turning the kaleidoscope: Innovations shaping the future of clinical trial design","authors":"Grégoire Marret, Mercedes Herrera, Lillian L. Siu","doi":"10.1016/j.ccell.2025.02.019","DOIUrl":"https://doi.org/10.1016/j.ccell.2025.02.019","url":null,"abstract":"Current clinical trials are based on rigid designs and drug-centric approaches that can stifle flexibility and innovation. With advances in molecular biology and technology, there is an urgent call to revitalize trial designs to meet these evolving demands. We propose a reshaped, prismatic vision of clinical trials combining different knowledge layers, synergized with modern computational approaches. This paradigm based on iterative learning will enable a more adaptive and precise framework for oncology drug development.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"17 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143608589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信